Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Linperlisib plus second-line standard of care in advanced solid tumors (Phase Ib/II)
ChiCTR2400088703Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of linperlisib in advanced nonhematological malignancy, colorectal cancer (CRC), gastric cancer (GC) and 3 more, sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Dose-limiting toxicity (DLT) and Overall response rate (ORR). Planned start Aug 2024; status: not yet recruiting.
02
Drugs
linperlisib
03
Conditions
advanced nonhematological malignancycolorectal cancer (CRC)gastric cancer (GC)pancreatic cancer (PC)breast cancer
Beyond the preview
Go deeper on ChiCTR2400088703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088703.